Back to Search
Start Over
Is Portal Venous Pressure Modulation Still Indicated for All Recipients in Living Donor Liver Transplantation?
- Source :
-
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society [Liver Transpl] 2018 Nov; Vol. 24 (11), pp. 1578-1588. - Publication Year :
- 2018
-
Abstract
- There is a consensus that portal venous pressure (PVP) modulation prevents portal hypertension (PHT) and consequent complications after adult-to-adult living donor liver transplantation (ALDLT). However, PVP-modulation strategies need to be updated based on the most recent findings. We examined our 10-year experience of PVP modulation and reevaluated whether it was necessary for all recipients or for selected recipients in ALDLT. In this retrospective study, 319 patients who underwent ALDLT from 2007 to 2016 were divided into 3 groups according to the necessity and results of PVP modulation: not indicated (n = 189), indicated and succeeded (n = 92), and indicated but failed (n = 38). Graft survival and associations with various clinical factors were investigated. PVP modulation was performed mainly by splenectomy to lower final PVP to ≤15 mm Hg. Successful PVP modulation improved prognosis to be equivalent to that of patients who did not need modulation, whereas failed modulation was associated with increased incidence of small-for-size syndrome (SFSS; P = 0.003) and early graft loss (EGL; P = 0.006). Among patients with failed modulation, donor age ≥ 45 years (hazard ratio [HR], 3.67; P = 0.02) and ABO incompatibility (HR, 3.90; P = 0.01) were independent risk factors for graft loss. Survival analysis showed that PVP > 15 mm Hg was related to poor prognosis in grafts from either ABO-incompatible or older donor age ≥ 45 years (P < 0.001), but it did not negatively affect grafts from ABO-compatible/identical and young donor age < 45 years (P = 0.27). In conclusion, intentional PVP modulation is not necessarily required in all recipients. Although grafts from both ABO-compatible/identical and young donors can tolerate PHT, lowering PVP to ≤15 mm Hg is a key to preventing SFSS and consequent EGL with grafts from either ABO-incompatible or older donors.<br /> (© 2018 by the American Association for the Study of Liver Diseases.)
- Subjects :
- Adult
Age Factors
Aged
Allografts blood supply
Consensus
Female
Graft Rejection epidemiology
Graft Rejection etiology
Graft Survival
Humans
Hypertension, Portal diagnosis
Hypertension, Portal epidemiology
Hypertension, Portal etiology
Ligation standards
Ligation statistics & numerical data
Liver blood supply
Liver Transplantation methods
Liver Transplantation standards
Male
Middle Aged
Portal Pressure physiology
Portal Vein physiopathology
Portasystemic Shunt, Surgical standards
Portasystemic Shunt, Surgical statistics & numerical data
Prognosis
Retrospective Studies
Risk Factors
Splenectomy standards
Splenectomy statistics & numerical data
Treatment Outcome
Young Adult
Graft Rejection prevention & control
Hypertension, Portal prevention & control
Liver Transplantation adverse effects
Living Donors
Subjects
Details
- Language :
- English
- ISSN :
- 1527-6473
- Volume :
- 24
- Issue :
- 11
- Database :
- MEDLINE
- Journal :
- Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
- Publication Type :
- Academic Journal
- Accession number :
- 29710397
- Full Text :
- https://doi.org/10.1002/lt.25180